Microbix Biosystems Inc. MBX.TO
Nov 3, 2026, 3:12 PM EST
- YTD
- +30.43%
- 1 year
- +15.38%
- Market cap
- 41.09M
- Revenue (ttm)
- 23.36M
- Profit margin
- 21.73%
- EPS (ttm)
- -0.04
- Shares out
- 134.53M
- Forward P/E
- 20.00
- YTD return
- +30.43%
- 1-year return
- +15.38%
- Volume
- 6.70K
- Avg volume
- 27.20K
- Open
- 0.31
- Previous close
- 0.29
- Day's range
- 0.30 – 0.31
- 52-week range
- 0.21 – 0.33
- Beta
- 0.34
- Analysts
- Strong Buy
- Price target
- 0.90 (+200.0%)
2Y -0.0100 (-3.13%)
Key statistics
- Enterprise value
- 42.76M
- PEG ratio
- 0.00
- Price / sales
- 2.30
- Price / book
- 1.95
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -8.50%
- Free cash flow
- -1.48M
- Total cash
- 12.81M
- Total debt
- 6.36M
- Return on equity
- 20.04%
- Short % of float
- 0.00%
- 50-day average
- 0.3308
- 200-day average
- 0.3413
Analyst view
Consensus: strong buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
About Microbix Biosystems Inc.
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for enabling the collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. It also provides customer vial filling services. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- microbix.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on MBX.TO — it syncs with the Stock Master app.